Autopsy report · NCT06048770

A Study of RBI-4000 in Healthy Participants

“Strategic business decision (not related to safety, efficacy, or quality)”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 11 months before it stopped.
• 89 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Replicate Bioscience

Sponsor type

Industry

Conditions

Healthy Volunteers

Interventions

RBI-4000; RabAvert

Participants

89

Sites

2

Countries

United States

Trials that died the same way

• Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)
  “Strategic business decision (not related to safety or efficacy concerns)” (97% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (87% match in meaning)
• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (83% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (83% match in meaning)
• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.